| Euronext Paris: COX
Nicox SA engages in the research, development and future commercialization of drug candidates. The company is applying its proprietary nitric oxide-donating research and development platform to develop an internal portfolio of new molecular entities for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases. Its pipeline includes several nitric oxide-donating new molecular, which are in development. The company has partnered with pharmaceutical and specialty pharmaceutical companies to enable it to maximize the value of its research and development platform and broad portfolio, while allowing the company to retain future commercialization rights in select areas. It was founded by Piero Del Soldato, Michele Garufi and Elizabeth Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France.